络活胶囊治疗痰瘀阻络型高血压病的临床研究

目的探讨络活胶囊对痰瘀阻络型高血压病的疗效和作用机理。方法 90例患者随机分为两组 ,分别用络活胶囊 (治疗组 ,6 0例 )和北京降压 0号 (对照组 ,30例 )治疗 ,疗程 4周 ,并对两组治疗前后血压、临床症状、血液流变学指标及血浆内皮素 (ET)、血管紧张素Ⅱ (AngⅡ )、一氧化氮 (NO)含量进行测定比较。结果临床症状总有效率治疗组 (83 3% )和对照组 (70 0 % )比较差异无显著性 ,但治疗组收缩压下降幅度优于对照组 (P <0 0 5 ) ;血液流变学指标、血浆NO含量、ET及AngⅡ水平治疗组治疗后均改善 (P <0 0 5或P <0 0 1)。对照组仅部分血液流变学指标、ET及AngⅡ水平治疗后有改善 (P <0 0 5或P <0 0 1)。结论络活胶囊对痰瘀阻络型高血压病有较好的疗效 ,其降压作用可能与改善患者血液流变学指标、升高NO含量、降低ET和AngⅡ水平有关。

英文摘要:

ObjectiveTo study the effect and mechanism of Luohuo capsule (LHC) in treating essential hypertension of Phlegm-stasis blocking Collateral type. MethodsNinety patients were randomly divided into two groups, the 60 patients in the treated group treated with LHC, and the 30 patients in the control group treated with Beijing Hypotension No. 0, the therapeutic course for both groups were 4 weeks. The changes of blood pressure, clinical symptoms, hemorrheologic parameters, plasma endothelin (ET), angiotensin Ⅱ (AngⅡ), nitric oxide (NO) level before and after treatment were observed. ResultsThe total effective rate of clinical symptoms in the treated and the control group was 83.3% and 70.0% respectively, with no significant difference between them, but the degree of systolic pressure reducing in the former were better than those in the latter (P<0 05). The levels of hemorrheological parameters, plasma NO, ET and AngⅡ in the treated group were all improved (P<0 01 or P<0 05), but in the control group, improvement only showed in part of the hemorrheological parameters, ET and AngⅡ levels. ConclusionLHC has quite a promising effect in treating essential hypertension of Phlegm-stasis blocking Collateral type, the mechanism might be related with the improvement of hemorrheological parameters, increasing blood NO level and decreasing ET and AngⅡ levels.

关闭